BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1718 related articles for article (PubMed ID: 8299185)

  • 1. [Lymphocytic infiltration in uveal melanoma].
    Sach J; Kocur J
    Cesk Oftalmol; 1993 Nov; 49(6):380-6. PubMed ID: 8299185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of lymphocytic infiltration in uveal melanoma.
    Durie FH; Campbell AM; Lee WR; Damato BE
    Invest Ophthalmol Vis Sci; 1990 Oct; 31(10):2106-10. PubMed ID: 2211008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemistry of infiltrating lymphocytes in uveal malignant melanoma.
    Whelchel JC; Farah SE; McLean IW; Burnier MN
    Invest Ophthalmol Vis Sci; 1993 Jul; 34(8):2603-6. PubMed ID: 8325762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prognostic role of morphological characteristics of the immune response in uveal melanoblastomas of various cellular types].
    Vit VV
    Arkh Patol; 1983; 45(7):25-30. PubMed ID: 6625934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Additive Role of Immune System Infiltration and Angiogenesis in Uveal Melanoma Progression.
    García-Mulero S; Alonso MH; Del Carpio LP; Sanz-Pamplona R; Piulats JM
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33800878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells.
    Bosch JJ; Thompson JA; Srivastava MK; Iheagwara UK; Murray TG; Lotem M; Ksander BR; Ostrand-Rosenberg S
    Cancer Res; 2007 May; 67(9):4499-506. PubMed ID: 17483366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monosomy of chromosome 3 and an inflammatory phenotype occur together in uveal melanoma.
    Maat W; Ly LV; Jordanova ES; de Wolff-Rouendaal D; Schalij-Delfos NE; Jager MJ
    Invest Ophthalmol Vis Sci; 2008 Feb; 49(2):505-10. PubMed ID: 18234992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor infiltrating lymphocytes in uveal melanoma: a link with clinical behavior?
    Staibano S; Mascolo M; Tranfa F; Salvatore G; Mignogna C; Bufo P; Nugnes L; Bonavolontà G; De Rosa G
    Int J Immunopathol Pharmacol; 2006; 19(1):171-9. PubMed ID: 16569355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Reaction of leukocyte migration inhibition in patients with uveal melanoblastoma].
    Nifontova TP
    Vopr Onkol; 1986; 32(4):57-61. PubMed ID: 3705529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cutaneous dysplastic naevi in uveal melanoma patients: markers for prognosis?
    Tóth-Molnár E; Hammer H; Oláh J
    Melanoma Res; 2000 Feb; 10(1):36-9. PubMed ID: 10711638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Uveal melanoma cell staining for CD34 and assessment of tumor vascularity.
    Chen X; Maniotis AJ; Majumdar D; Pe'er J; Folberg R
    Invest Ophthalmol Vis Sci; 2002 Aug; 43(8):2533-9. PubMed ID: 12147581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Digital PCR-Based T-cell Quantification-Assisted Deconvolution of the Microenvironment Reveals that Activated Macrophages Drive Tumor Inflammation in Uveal Melanoma.
    de Lange MJ; Nell RJ; Lalai RN; Versluis M; Jordanova ES; Luyten GPM; Jager MJ; van der Burg SH; Zoutman WH; van Hall T; van der Velden PA
    Mol Cancer Res; 2018 Dec; 16(12):1902-1911. PubMed ID: 30093564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-infiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma.
    Mäkitie T; Summanen P; Tarkkanen A; Kivelä T
    Invest Ophthalmol Vis Sci; 2001 Jun; 42(7):1414-21. PubMed ID: 11381040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human leukocyte antigen class I expression. Marker of poor prognosis in uveal melanoma.
    Blom DJ; Luyten GP; Mooy C; Kerkvliet S; Zwinderman AH; Jager MJ
    Invest Ophthalmol Vis Sci; 1997 Aug; 38(9):1865-72. PubMed ID: 9286277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autocrine secretion of Fas ligand shields tumor cells from Fas-mediated killing by cytotoxic lymphocytes.
    Hallermalm K; De Geer A; Kiessling R; Levitsky V; Levitskaya J
    Cancer Res; 2004 Sep; 64(18):6775-82. PubMed ID: 15374996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of Fas and Fas ligand in uveal melanoma: biological implication and prognostic value.
    Anastassiou G; Coupland SE; Stang A; Boeloeni R; Schilling H; Bornfeld N
    J Pathol; 2001 Aug; 194(4):466-72. PubMed ID: 11523055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MRI for the evaluation of scleral invasion and extrascleral extension of uveal melanomas.
    Récsán Z; Karlinger K; Fodor M; Zalatnai A; Papp M; Salacz G
    Clin Radiol; 2002 May; 57(5):371-6. PubMed ID: 12014934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AgNOR values in Callender histopathological types of malignant uveal melanomas.
    Mera M
    Rom J Morphol Embryol; 1995; 41(3-4):125-8. PubMed ID: 8772368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prospects for developing treatment of uveal melanoma from the position of modern carcinogenesis concepts].
    Likhvantseva VG
    Vestn Oftalmol; 2002; 118(1):32-5. PubMed ID: 11898358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Retrospective study of uveal melanoma].
    Tóth J
    Magy Onkol; 2005; 49(1):19-25. PubMed ID: 15902329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 86.